The startup develops a non-invasive treatment for chronic sinusitis using a proprietary multimodal frequency system that targets facial pain and alleviates sinus symptoms without medication. This approach enables healthcare providers to enhance patient outcomes by improving pain and sinus symptom scores.
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic sinusitis affects millions, and current treatments often involve invasive procedures, antibiotics, or nasal decongestants, which may have limited effectiveness or undesirable side effects. There are currently no approved medications for chronic sinusitis in the USA or EU.
Solution
AxioSonic is developing a non-invasive, at-home treatment for sinusitis using a handheld device that delivers a proprietary multi-modal ultrasonic system. The device is designed to disrupt biofilm within the sinuses, reduce inflammation, and alleviate symptoms without the need for surgery or medication. Integrated vibratory feedback provides a unique user experience. Clinical studies have demonstrated statistically significant improvements in pain scores and sinus symptom scores, with a high percentage of patients showing a reduction in sinus inflammation.
Target Audience
The primary target audience includes individuals suffering from chronic sinusitis seeking a non-invasive, at-home treatment option, as well as healthcare providers looking for effective alternatives to traditional methods.
Features
- Handheld device for at-home use
- Proprietary multi-modal ultrasonic system
- Disrupts biofilm in the sinuses
- Reduces inflammation
- Provides symptom relief
- Integrated vibratory feedback